Search

Your search keyword '"Gheorghe, Liana"' showing total 8 results
Start Over Author "Gheorghe, Liana" Language undetermined
8 results on '"Gheorghe, Liana"'

1. The risks of hepatocellular carcinoma and variceal bleeding after HCV eradication with direct-acting antiviral therapy: a propensity score analysis

Author

Preda Carmen, Dimache Mihaela, Girleanu Irina, M Manolache, Iacob Speranta, Cojocariu Camelia, Miftode Egidia, Huiban Laura, Muzica Cristina Maria, Trifan Anca, Carol Stanciu, Catalin Sfarti, Tudor Cuciureanu, Cijevschi Prelipcean Cristina, Singeap Ana Maria, Gheorghe Liana, Pop Corina, Mihai Catalina, Ciortescu Irina, and Stefanescu Gabriela

Subjects
medicine.medical_specialty, Dasabuvir, business.industry, Ribavirin, General Medicine, medicine.disease, Gastroenterology, digestive system diseases, Ombitasvir, chemistry.chemical_compound, Esophageal varices, chemistry, Paritaprevir, Hepatocellular carcinoma, Internal medicine, medicine, Ritonavir, Decompensation, business, medicine.drug
Abstract

The combination paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD), which achieves a high sustained virologic response (SVR) rate and few side effects, has dramatically changed the outcome of hepatitis C virus (HCV) infection. The risk of hepatocellular carcinoma (HCC) and variceal bleeding in patients treated with interferon (IFN)-free direct-acting antivirals (DAAs) is unknown. The aim of this prospective study was to evaluate the rate of HCC and variceal bleeding and identify prognostic factors for decompensation/complications in HCV-1b-infected patients with compensated liver cirrhosis following treatment with PrOD with or without ribavirin. Material and methods: A total of 483 HCV patients received PrOD treatment. Patients with a history of HCC were excluded from the study. Prior antiviral therapy was identified in 59% of patients. Patient data were collected at baseline, at the end of treatment (EoT), at 3 months after EOT (SVR) and during an 18-month surveillance period. Patients were divided into two age groups

Published
2021

2. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe

Author

Marshall, Alison D., Cunningham, Evan B., Nielsen, Stine, Aghemo, Alessio, Alho, Hannu, Backmund, Markus, Bruggmann, Philip, Dalgard, Olav, Seguin-Devaux, Carole, Flisiak, Robert, Foster, Graham R., Gheorghe, Liana, Goldberg, David, Goulis, Ioannis, Hickman, Matthew, Hoffmann, Patrick, Jancorienė, Ligita, Jarcuska, Peter, Kåberg, Martin, Kostrikis, Leondios G., Makara, Mihály, Maimets, Matti, Marinho, Rui Tato, Matičič, Mojca, Norris, Suzanne, Ólafsson, Sigurður, Øvrehus, Anne, Pawlotsky, Jean-Michel, Pocock, James, Robaeys, Geert, Roncero, Carlos, Simonova, Marieta, Sperl, Jan, Tait, Michele, Tolmane, Ieva, Tomaselli, Stefan, van der Valk, Marc, Vince, Adriana, Dore, Gregory J., Lazarus, Jeffrey V., Grebely, Jason, International Network on Hepatitis in Substance Users (INHSU), Kostrikis, Leondios G. [0000-0002-5340-7109], Infectious diseases, AII - Infectious diseases, AII - Amsterdam institute for Infection and Immunity, APH - Digital Health, APH - Personalized Medicine, and APH - Global Health

Subjects
hepatitis C virus, HIV Infections, chemistry.chemical_compound, 0302 clinical medicine, Antiviral Agents/economics, HIV-HCV co-infection, 030212 general & internal medicine, Reimbursement, liver fibrosis, media_common, Dasabuvir, Coinfection, Health Policy, Gastroenterology, Hepatitis C, 3. Good health, Europe, Hepatitis C, Chronic/complications, Insurance, Health, Reimbursement, 030211 gastroenterology & hepatology, Switzerland, medicine.drug, medicine.medical_specialty, HIV Infections/complications, Antiviral Agents, Drug Costs, 03 medical and health sciences, hepatitis C treatment, medicine, Humans, media_common.cataloged_instance, European Union, European union, PWID, Intensive care medicine, Hepatitis, direct-acting antiviral, Hepatology, business.industry, Hepatitis C, Chronic, alcohol use, medicine.disease, reimbursement, Virology, Ombitasvir, chemistry, Paritaprevir, Ritonavir, business, treatment restrictions
Abstract

All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver. 3 2 125 133

Published
2018

4. A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis

Author

Gheorghe, Liana, Iacob, Speranta, Simionov, Iulia, Caruntu, Florin, Motoc, Adriana, Arama, Victoria, Liliana Preotescu, Stefan, Ion, Goldis, Adrian, Brisc, Cristian, Rugina, Sorin, and Rednic, Nicolae

Subjects
Adult, Liver Cirrhosis, Male, Adolescent, Genotype, Proline, Gastroenterology, Interferon-alpha, Hepacivirus, Hepatitis C, Chronic, Interferon alpha-2, Middle Aged, Viral Load, Prognosis, Antiviral Agents, Recombinant Proteins, Young Adult, Treatment Outcome, Ribavirin, Humans, RNA, Viral, Drug Therapy, Combination, Female, Prospective Studies, Aged
Abstract

Background: A number of high quality randomized clinical trials examining the efficacy and safety of triple therapy in genotype-1 HCV-infected patients have been published. However, these trials included a small number of patients with advanced fibrosis, and selected a population different from that in real-world settings.Aim: To determine the efficacy of boceprevir, pegInterferon and ribavirin regimen in genotype-1 treatment-experienced HCV-infected patients with cirrhosis and bridging fibrosis in real-life setting.Method: 167 treatment-experienced patients (85.6% relapsers) out of which 33.5% had cirrhosis, with a mean age of 52.6 years, registered in the Romanian Name Patient Program Database were included into the study.Results: 16.7% of patients had a viral load >100 IU/mL. Undetectable HCV RNA was encountered in 77.3% of patients at week 12. Multiple logistic regression analysis revealed the following independent predictors, measured at week 8, for an HCV RNA ≥100 IU/mL at week 12 of triple therapy: alanine aminotransferase values (p=0.01), hemoglobin level (p=0.04) and

Published
2014

6. The Value of Contrast Enhanced Ultrasound (CEUS) for Focal Liver Lesions Characterization - A Multicenter Romanian Study

Author

Sporea, Ioan, Badea, Radu I., Popescu, Alina, Sparchez, Zeno, Sirli, Roxana, Danila, Mirela, Sandulescu, Larisa D., Bota, Simona, Calescu, Dorina Pestroiu, Prelipcean, Cristina Cijevschi, Mihai, Catalina, Nedelcu, Dana, Brisc, Ciprian, Ciobaca, Lucian, Saftoiu, Adrian, Gheorghe, Liana S., Mihai Adrian Socaciu, Martie, Alina F., Ioanitescu, Simona, Tamas, Attila, Streba, Costin T., Iordache, Mihaela, Simionov, Iulia I., Jinga, Mariana, and Anghel, Adrian

7. The influence of clinical significant portal hypertension (stage Baveno 2) on safety, tolerability and efficacy of paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin (PrOD plus R) in a real-world large cohort of genotype 1b HCV liver cirrhosis patients

Author

Trifan, Anca, Singeap, Ana Maria, Gheorghe, Liana, Curescu, Manuela G., Cijevschi, Cristina, Brisc, Ciprian, Cojocariu, Camelia, Stefanescu, Gabriela V., Mihai, Catalina, Simona Maria Bataga, Miftode, Egidia, Arama, Victoria, Rogoveanu, Ion, Sporea, Ioan, Goldis, Adrian, Suceveanu, Andra I., Iacob, Speranta, Girleanu, Irina, and Stanciu, Carol

8. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

Author

Wolfgang Vogel, M. Blachier, Lelia Thornton, Wim Laleman, Ieva Tolmane, Antonio Craxì, Mojca Matičič, Hans Van Vlierberghe, Christoph Sarrazin, Laura Harcouet, Joël Mossong, Ilias Gountas, Matthew E. Cramp, Devin Razavi-Shearer, Soo Aleman, Lyudmila Mateva, Ann-Sofi Duberg, Vratislav Nemecek, Jordan Genov, Michael Manns, Anne Øvrehus, Irena Hrstić, Kimberly Murphy, Stefano Vella, Krzysztof Tomasiewicz, Francesco Negro, Nina Weis, Antonio Javier Blasco, Agita Jeruma, Karolin Falconer, Danute Speiciene, Jonas Valantinas, Jose Luis Calleja, Jan Sperl, Gabor Horvath, Filipe Calinas, Peter Jarcuska, Jerneja Videčnik-Zorman, Ivan Schréter, Kathryn Razavi-Shearer, Christophe Moreno, Sergeja Gregorčič, Angelos Hatzakis, Pierre Van Damme, Riina Salupere, Massimo Colombo, Robert J. de Knegt, Peter J Smit, Dijana Nonkovic, Daniela K van Santen, Waldemar Halota, Rui Sarmento-Castro, Jean-Michel Delile, Suzanne Norris, Vana Sypsa, Robert Flisiak, Carole Seguin-Devaux, Martin Lagging, Liana Gheorghe, Mihály Makara, Javier García-Samaniego, Christophe Hézode, Jennifer Kieran, Marian Oltman, Peter Stärkel, Victor de Ledinghen, Pablo Lázaro, Stefan Zeuzem, E. A. Croes, Patrick Hoffmann, Matti Maimets, Francesco Saverio Mennini, Kostas Athanasakis, Chris Estes, Stephen D. Ryder, Sarah Robbins, Françoise Roudot-Thoraval, Martin Kåberg, Kaarlo Simojoki, Sona Frankova, Adrian Goldis, Marietta Simonova, Kyriakos Souliotis, Ken Pasini, Homie Razavi, Rui Tato Marinho, Sarah Blach, Pavol Kristian, Rumiana Mitova, Loreta A. Kondili, Maria Buti, Helen Nde, Boris Lukšić, Henrik Krarup, Dominique Vandijck, Henk W. Reesink, David A. M. C. van de Vijver, Iskren Kotzev, Jessie Gunter, Adriaan J. van der Meer, Martti Färkkilä, Baiba Rozentale, Perttu Arkkila, Krasimir Antonov, Jan Gerstoft, Béla Hunyady, Peer Brehm Christensen, Ivane Gamkrelidze, Valentina Liakina, Michael Gschwantler, Deian Jelev, Tatjana Reic, George V. Papatheodoridis, Jonathan Schmelzer, Daniel Struck, Gastroenterology & Hepatology, Razavi, Homie, Robbins, Sarah, Zeuzem, Stefan, Negro, Francesco, Buti, Maria, Duberg, Ann-Sofi, Roudot-Thoraval, Françoise, Craxi, Antonio, Manns, Michael, Marinho, Rui T, Hunyady, Bela, Colombo, Massimo, Aleman, Soo, Antonov, Krasimir, Arkkila, Perttu, Athanasakis, Kosta, Blach, Sarah, Blachier, Martin, Blasco, Antonio J, Calinas, Filipe, Calleja, Jose L, Christensen, Peer B, Cramp, Matthew E, Croes, Esther, de Knegt, Robert J, de Ledinghen, Victor, Delile, Jean-Michel, Estes, Chri, Falconer, Karolin, Färkkilä, Martti, Flisiak, Robert, Frankova, Sona, Gamkrelidze, Ivane, García-Samaniego, Javier, Genov, Jordan, Gerstoft, Jan, Gheorghe, Liana, Goldis, Adrian, Gountas, Ilia, GregorÄ iÄ , Sergeja, Gschwantler, Michael, Gunter, Jessie, Halota, Waldemar, Harcouet, Laura, Hézode, Christophe, Hoffmann, Patrick, Horvath, Gabor, Hrstic, Irena, JarÄ uÅ¡ka, Peter, Jelev, Deian, Jeruma, Agita, KÃ¥berg, Martin, Kieran, Jennifer, Kondili, Loreta A, Kotzev, Iskren, Krarup, Henrik, Kristian, Pavol, Lagging, Martin, Laleman, Wim, Lázaro, Pablo, Liakina, Valentina, LukÅ¡iÄ , Bori, Maimets, Matti, Makara, Mihály, Mateva, Lyudmila, Maticic, Mojca, Mennini, Francesco S, Mitova, Rumiana, Moreno, Christophe, Mossong, Joel, Murphy, Kimberly, Nde, Helen, Nemecek, Vratislav, Nonkovic, Dijana, Norris, Suzanne, Oltman, Marian, à vrehus, Anne L H, Papatheodoridis, George, Pasini, Ken, Razavi-Shearer, Devin, Razavi-Shearer, Kathryn, Reesink, Henk W, Reic, Tatjana, Rozentale, Baiba, Ryder, Stephen D, Salupere, Riina, Sarmento-Castro, Rui, Sarrazin, Christoph, Schmelzer, Jonathan D, Schréter, Ivan, Seguin-Devaux, Carole, Simojoki, Kaarlo, Simonova, Marietta, Smit, Peter J, Souliotis, Kyriako, Speiciene, Danute, Sperl, Jan, Stärkel, Peter, Struck, Daniel, Sypsa, Vana, Thornton, Lelia, Tolmane, Ieva, Tomasiewicz, Krzysztof, Valantinas, Jona, Van Damme, Pierre, van de Vijver, David, van der Meer, Adriaan J, van Santen, Daniela, Van Vlierberghe, Han, Vandijck, Dominique, Vella, Stefano, VideÄ nik-Zorman, Jerneja, Vogel, Wolfgang, Weis, Nina, Hatzakis, Angelos, European Union HCV Collaborators, and Faculteit Medische Wetenschappen/UMCG

Subjects
Pediatrics, ddc:616.07, medicine.disease_cause, 0302 clinical medicine, Cost of Illness, Epidemiology, Prevalence, EPIDEMIOLOGY, 030212 general & internal medicine, Settore SECS-P/01 - Economia Politica, CIRRHOSIS, media_common, ddc:616, Antiviral Agents/therapeutic use, education.field_of_study, INJECT DRUGS, Gastroenterology, HCV INFECTION, virus diseases, Hepatitis C, Emigration and Immigration, DISEASE BURDEN, Markov Chains, Emigration and Immigration/statistics & numerical data, 030211 gastroenterology & hepatology, Viral hepatitis, Modelling, Eradication, European Union, prevalence, COUNTRIES, medicine.medical_specialty, Hepatitis C virus, Population, UNITED-STATES, World Health Organization, Antiviral Agents, 03 medical and health sciences, SDG 3 - Good Health and Well-being, PEOPLE, Internal medicine, Intervention (counseling), medicine, Journal Article, media_common.cataloged_instance, Humans, Viremia, European union, Disease Eradication, education, Hepatitis C/diagnosis/drug therapy/epidemiology/prevention & control, Hepatology, business.industry, Viremia/diagnosis/drug therapy/epidemiology/prevention & control, medicine.disease, Virology, PREVENTION, digestive system diseases, Human medicine, VIRAL-HEPATITIS, business
Abstract

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 2016, and a Delphi process to gain expert consensus and validate inputs. We aggregated country models to create a regional EU model. We used the EU model to forecast HCV disease progression (considering the effect of immigration) and developed a strategy to acehive WHO targets. We used weighted average sustained viral response rates and fibrosis restrictions to model the effect of current therapeutic guidelines. We used the EU model to forecast HCV disease progression (considering the effect of immigration) under current screening and therapeutic guidelines. Additionally, we back-calculated the total number of patients needing to be screened and treated to achieve WHO targets. Findings We estimated the number of viraemic HCV infections in 2015 to be 3 238 000 (95% uncertainty interval [UI] 2 106 000–3 795 000) of a total population of 509 868 000 in the EU, equating to a prevalence of viraemic HCV of 0·64% (95% UI 0·41–0·74). We estimated that 1 180 000 (95% UI 1 003 000–1 357 000) people were diagnosed with viraemia (36·4%), 150 000 (12 000–180 000) were treated (4·6% of the total infected population or 12·7% of the diagnosed population), 133 000 (106 000–160 000) were cured (4·1%), and 57 900 (43 900–67 300) were newly infected (1·8%) in 2015. Additionally, 30 400 (26 600–42 500) HCV-positive immigrants entered the EU. To achieve WHO targets, unrestricted treatment needs to increase from 150 000 patients in 2015 to 187 000 patients in 2025 and diagnosis needs to increase from 88 800 new cases annually in 2015 to 180 000 in 2025. Interpretation Given its advanced health-care infrastructure, the EU is uniquely poised to eliminate HCV; however, expansion of screening programmes is essential to increase treatment to achieve the WHO targets. A united effort, grounded in sound epidemiological evidence, will also be necessary. Funding Gilead Sciences.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results